Lakefront Biotherapeutics Completes Sale Of Early-Stage Cell Therapy Pipeline To Armed Cell Therapeutics For €8M Upfront, Up To $230M In Milestones
Share
Why It Matters
Lakefront sold early-stage projects to another company for cash now. This shows the company is raising money by selling future opportunities.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.